Insider Trading Alert - NPSP, GPI And JDSU Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 4, 2014, 99 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $25.55 to $17,507,243.40.

Highlighted Stocks Traded by Insiders:

NPS Pharmaceuticals (NPSP) - FREE Research Report

Beshar Luke M, who is Evp & Cfo at NPS Pharmaceuticals, sold 10,000 shares at $29.00 on Nov. 4, 2014. Following this transaction, the Evp & Cfo owned 72,780 shares meaning that the stake was reduced by 12.08% with the 10,000-share transaction.

The shares most recently traded at $27.22, down $1.78, or 6.54% since the insider transaction. Historical insider transactions for NPS Pharmaceuticals go as follows:

  • 4-Week # shares sold: 30,635
  • 12-Week # shares sold: 30,635
  • 24-Week # shares sold: 30,635

The average volume for NPS Pharmaceuticals has been 2.2 million shares per day over the past 30 days. NPS Pharmaceuticals has a market cap of $2.9 billion and is part of the health care sector and drugs industry. Shares are down 10.47% year-to-date as of the close of trading on Tuesday.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company has a P/E ratio of 682.2. Currently, there are 7 analysts who rate NPS Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NPSP - FREE

TheStreet Quant Ratings rates NPS Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Get the full NPS Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Group 1 Automotive (GPI) - FREE Research Report

Hesterberg Earl J, who is President & CEO at Group 1 Automotive, sold 10,000 shares at $84.74 on Nov. 4, 2014. Following this transaction, the President & CEO owned 442,621 shares meaning that the stake was reduced by 2.21% with the 10,000-share transaction.

The shares most recently traded at $85.24, up $0.50, or 0.59% since the insider transaction. Historical insider transactions for Group 1 Automotive go as follows:

  • 4-Week # shares sold: 19,000
  • 12-Week # shares sold: 34,527
  • 24-Week # shares sold: 34,527

The average volume for Group 1 Automotive has been 335,300 shares per day over the past 30 days. Group 1 Automotive has a market cap of $2.1 billion and is part of the services sector and specialty retail industry. Shares are up 18.19% year-to-date as of the close of trading on Tuesday.

Group 1 Automotive, Inc., through its subsidiaries, operates in the automotive retail industry. The stock currently has a dividend yield of 0.8%. The company has a P/E ratio of 21.1. Currently, there are 3 analysts who rate Group 1 Automotive a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GPI - FREE

TheStreet Quant Ratings rates Group 1 Automotive as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Group 1 Automotive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

JDS Uniphase Corp (CA (JDSU) - FREE Research Report

Scrivanich Luke M, who is Svp, Osp at JDS Uniphase Corp (CA, sold 12,435 shares at $13.67 on Nov. 4, 2014. Following this transaction, the Svp, Osp owned 12,638 shares meaning that the stake was reduced by 49.6% with the 12,435-share transaction.

The shares most recently traded at $13.56, down $0.11, or 0.83% since the insider transaction. Historical insider transactions for JDS Uniphase Corp (CA go as follows:

  • 4-Week # shares sold: 196
  • 12-Week # shares sold: 196
  • 24-Week # shares sold: 196

The average volume for JDS Uniphase Corp (CA has been 5.3 million shares per day over the past 30 days. JDS Uniphase Corp (CA has a market cap of $3.1 billion and is part of the technology sector and telecommunications industry. Shares are up 3.74% year-to-date as of the close of trading on Tuesday.

JDS Uniphase Corporation provides network and service enablement solutions and optical products worldwide. Currently, there are 6 analysts who rate JDS Uniphase Corp (CA a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JDSU - FREE

TheStreet Quant Ratings rates JDS Uniphase Corp (CA as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full JDS Uniphase Corp (CA Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home